Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM97MGE)

Drug Name

N-(2-hydroxyethyl)linoleoylamide Drug Info

Synonyms

Linoleamide MEA; Linoleoyl ethanolamide; Linoleic ethanolamide; n-linoleoylethanolamine; N-(2-Hydroxyethyl)linoleamide; Anandamide (18:2, n-6); Linoleoyl monoethanolamide; UNII-889DYX0816; N-(2-hydroxyethyl)linoleoylamide; Linoleylethanolamide; 68171-52-8; Monoethanolamine linoleic acid amide; EINECS 269-029-6; N-(9Z,12Z-octadecadienoyl)-ethanolamine; CHEMBL149859; N-(2-Hydroxyethyl)-linoleamide; C20H37NO2; CHEBI:64032; 889DYX0816; (9Z,12Z)-N-(2-Hydroxyethyl)octadeca-9,12-dien-1-amide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5283446
ChEBI ID: CHEBI:64032
CAS Number: CAS 68171-52-8
TTD Drug ID: DM97MGE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Fatty acid amide hydrolase (FAAH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[2]
Thiopental	DMGP8AX	Anaesthesia	9A78.6	Approved	[3]
JNJ-42165279	DM72GZO	Anxiety disorder	6B00-6B0Z	Phase 2	[4]
SSR411298	DMGTB2Q	Major depressive disorder	6A70.3	Phase 2	[5]
IW-6118	DMP42W1	Inflammation	1A00-CA43.1	Phase 2	[6]
PF-04457845	DMPRYU1	Liver disease	DB90-BD99	Phase 2	[7]
IPI-940	DMEIM5G	Pain	MG30-MG3Z	Phase 1	[8]
PMID29053063-Compound-11d	DMDRK68	N. A.	N. A.	Patented	[9]
Piperazine carbamic compound 1	DMZSYU4	N. A.	N. A.	Patented	[9]
Piperazine carbamic compound 2	DMMQ0ZO	N. A.	N. A.	Patented	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fatty acid amide hydrolase (FAAH)	TTDP1UC	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Radiosynthesis, in vitro and in vivo evaluation of 123I-labeled anandamide analogues for mapping brain FAAH. Bioorg Med Chem. 2009 Jan 1;17(1):49-56.
2	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
3	The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6	The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
7	Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
9	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.